Clinical trial · Interventional
Hyperpolarized 13C MRI for Cancer Immunotherapy
Next Generation Precision Imaging for Cancer Immunotherapy: Dynamic Nuclear Polarization and Metabolomics Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aim to develop an advanced imaging platform, such as dynamic nuclear polarization (DNP) 13C-MRI, MR fingerprinting (MRF) and MR Relaxometry, which combines with traditional anatomical contrast CT, MRI and PET, and integrate blood/urine metabolomics methods. A comprehensive strategy to thoroughly analyze the immune activation of spleen pattern, microstructure, cell density, red blood cell iron content, immune cell glycolysis and metabolic flow rate.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperpolarized 13C-Pyruvate injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Conventional Imaging Group
- description
- 60 participants who accepted ICI treatment will receive conventional imaging
- type
- EXPERIMENTAL
- label
- Next Generation Imaging Group
- description
- 30 participants who accepted ICI treatment will receive next generation imaging including MRF and MR Relaxometry and hyperpolarized 13C pyruvate DNP scanning.
- interventionNames
- Drug: Hyperpolarized 13C-Pyruvate injection
Primary outcomes (6)
- measure
- DNP conversion flux ( pyruvate-to-lactate conversion rate; Kpl) before immunotherapy
- timeFrame
- ~1-2 weeks before clinical immunotherapies
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosed or recurrent gynecological cancer confirmed by histology. 2. Age ≥ 20 years old. 3. Expected to receive immunotherapy. Exclusion Criteria: 1. Suffering from other malignancies (excluding non-melanoma skin cancer). 2. History of splenic abnormalities (such as splenic damage, cirrhosis-related splenomegaly or primary/metastatic splenic tumors). 3. Insufficient function of bone marrow, liver and kidney. 4. Contraindications to MRI studies (e.g. claustrophobia, cardiac pacemaker, metal implants in the pelvis). 5. Uncontrolled concurrent diseases, including but not limited to kidney stones, persistent or active infection, symptomatic heart failure, unstable angina, cardiac arrhythmias, or mental illness/social situations that limit compliance with research requirements. 6. Pregnant or lactating women.
References
Publications (0)
Data not yet available